Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby br…
Drug Manufacturers - General
US, New Brunswick [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 1.21 | 1.17 | 1.16 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -26.57 | 1.06 | 1.44 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.77 | 29.08 | 28.57 | |
| Cash | 14.31 | 10.89 | 9.52 | |
| Capex | 49.23 | -0.34 | -0.66 | |
| Free Cash Flow | -54.59 | 1.18 | 2.61 | |
| Revenue | -0.08 | 8.88 | 8.89 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 2.20 | 0.69 | 0.67 | |
| Operating Margin | 43.62 | 0.28 | 0.19 | |
| ROA | -21.67 | 0.02 | 0.02 | |
| ROE | -21.04 | 0.05 | 0.06 | |
| ROIC | 39.08 | 0.05 | 0.04 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of JNJ is permitted for members.
5
Growth
The "Growth Entry" for the Focus of JNJ is permitted for members.
6
Leverage & Liquidity